BACKGROUND: REV-ERBa has been shown to regulate adipogenesis and lipid metabolism as well as to link the circadian timing system to whole body metabolic homeostasis. We thus tested whether polymorphisms in REV-ERBa could be associated with metabolic phenotypes in human population samples. METHODS: We analyzed the associations between 5 REV-ERBa polymorphisms and anthropometric (body weight, body mass index (BMI), waist and hip circumferences), biochemical (plasma lipid, glucose and insulin levels) and clinical (systolic and diastolic blood pressure) variables in three population-based studies (MONICA Lille n ¼ 1155 adults, MONA LISA Lille n ¼ 1170 adults and HELENA n ¼ 1155 adolescents). We assessed in vitro, the potential influence of one REV-ERBa polymorphism in transient transfection assays using two different cell lines. RESULTS: We observed significant and consistent associations between the T minor allele of the REV-ERBa rs2071427 polymorphism (located in intron 1) and higher BMI (mean allele effect ¼ þ 0.33 kg m À 2 ) in the MONICA Lille (P ¼ 0.02), MONA LISA (P ¼ 0.02) and HELENA (P ¼ 0.03) studies. The odds ratios for obesity associated with this allele were 1.67 (1.00-2.79) (P ¼ 0.05) in MONICA Lille, 1.29 (1.01-1.65) (P ¼ 0.04) in MONA LISA Lille and the odds ratio for overweight was 1.48 (1.08-2.03) (P ¼ 0.01) in HELENA. In transfection experiments in human hepatocyte-derived cell lines, the REV-ERBa intron 1 directed the transcription of a luciferase reporter gene independently of the rs2071427 polymorphism. CONCLUSION: Our results suggest that the REV-ERBa rs2071427 polymorphism modulates body fat mass in both adult and young people. Keywords: REV-ERBa; NR1D1; polymorphism; BMI; adult and young population; fat mass INTRODUCTION Accumulating evidence from epidemiological and experimental studies supports the notion that metabolic homeostasis and the circadian clock system are intimately linked in mammals. Circadian clocks are time-keeping systems that allow organisms to adapt their physiology and behavior to the predictable changes in their environment resulting from rotation of the earth.
INTRODUCTION
Accumulating evidence from epidemiological and experimental studies supports the notion that metabolic homeostasis and the circadian clock system are intimately linked in mammals. Circadian clocks are time-keeping systems that allow organisms to adapt their physiology and behavior to the predictable changes in their environment resulting from rotation of the earth. 1 Misalignment of the human circadian system alters metabolic parameters and could represent an overlooked risk factor for the development of metabolic disorders. 2, 3 This is further exemplified by recent work showing that genetic ablation of the clock function in mice leads to a metabolic syndrome like phenotype including obesity and diabetes. [4] [5] [6] Conversely, metabolic challenges such as high fat feeding disrupt the circadian system. 7 The REV-ERBa protein, encoded by the NR1D1 gene, is an orphan nuclear receptor that regulates gene transcription through binding as homo-or heterodimer to specific DNA sequences located in enhancer regions of their target genes, whereas interacting with coregulators including histone-modifying enzymes and chromatin remodelers to repress or activate gene transcription. 8 REV-ERBa has been identified as a core component of the circadian clock mechanism in mammals. 9, 10 REV-ERBa was shown to be a target of PPARg during the adipocyte differentiation process and to regulate apolipoprotein CIII gene expression in mouse and human liver. [11] [12] [13] Then, several independent studies have linked the circadian regulation of REV-ERBa to gluconeogenesis, lipogenesis, bile acid metabolism and gluconeogenesis. [14] [15] [16] [17] In this context, REV-ERBa has emerged as a potentially relevant link between the circadian timing system and metabolic processes. [18] [19] [20] [21] Importantly, the discovery of heme as an unconventional endogenous REV-ERBa ligand suggests that the pharmacological modulation of REV-ERBa activity could become a novel therapeutic approach in the treatment of metabolic disorders. [22] [23] [24] [25] Very few studies assessed the impact of genetic polymorphisms in the REV-ERBa gene in human population samples. All of them concerned mood disorders, especially bipolar disorder, and showed conflicting results. [26] [27] [28] [29] [30] Even, if the implication of REV-ERBa in metabolic pathways is now well documented, the impact of the REV-ERBa gene variability on metabolic phenotypes in humans remains unknown. 1 To address this question, we explored the associations between tagSNPs of REV-ERBa and anthropometric (body weight, BMI, waist and hip circumferences), biochemical (plasma lipid, glucose and insulin levels) and clinical (systolic and diastolic blood pressure) parameters in three independent population samples.
SUBJECTS AND METHODS Subjects
The MONICA Lille and MONA LISA Lille studies. Participants were recruited in the framework of the World Health Organization MONICA population survey, 31 between 1996 and 1997 (MONICA, n ¼ 1155) or between 2006 and 2007 (MONA LISA, n ¼ 1578) in the Lille Urban Community in Northern France. The protocol was approved by the appropriate independent ethics committees. Subjects (aged 35-64 years in the 1st survey or 35-74 years in the 2nd survey) were selected randomly from electoral rolls after stratification by town size, sex and age, in order to obtain 200 participants for each sex and each 10-year age group. To our knowledge, participants to the MONICA study were not included in the MONA LISA study. Details of the studies have been described elsewhere. 32, 33 After providing written informed consent, participants filled out a standard questionnaire, and physical measurements were taken by a specially trained nurse. The questionnaire covered questions on physical activity, alcohol consumption, smoking status, personal & family medical history, attitudes and knowledge concerning several diseases and any current medication use. Physical activity was defined as at least a 15-min walk a day, and/or lifting or carrying heavy objects at work every day and/or sport or physical exercise for 42 h a week. In terms of smoking exposure, individuals were categorized as never-smokers, former smokers and current smokers (that is, individuals reporting at least one cigarette per day). Alcohol intake was expressed as the total number of milliliters of alcohol per week from wine, beer, cider and spirits. Anthropometric measurements including body weight were taken on individuals in light clothing without shoes. The BMI was calculated according to the Quetelet equation. Obesity was considered for BMI equal or above 30 kg m À 2 . Percentage of body fat was obtained by tetrapolar bioelectrical impedance analysis by use of a TANITA 300 GS scale (Tanita, Amsterdam, The Netherlands). Blood pressure was measured on the right arm, with the subject in a sitting position and after a minimum 5-min rest, using a standard mercury sphygmomanometer. The mean value of two consecutive blood pressure readings was taken into account. A 20 ml blood sample was drawn into a disodium ethylene diamine tetra acetic acid tube (after the subjects had fasted for at least 10 h). Cholesterol and triglyceride levels were measured using enzyme assays (Boehringer Mannheim for MONICA and Olympus for MONA LISA). High-density lipoprotein cholesterol was measured after sodium phosphotungstate/ magnesium chloride precipitation (Boehringer Mannheim for MONICA and Olympus for MONA LISA). Plasma low-density lipoprotein cholesterol was calculated with the Friedewald equation when triglyceride levels were o4.56 mM. Plasma glucose was measured using the standard glucose hexokinase method (DuPont Dimension, Brussels, Belgium). Plasma insulin was measured by radio-immunoassay (Medgenix Diagnostics, Brussels, Belgium) for MONICA and by enzyme immunoassay (Beckman Coulter, Villepinte, France) or an immunoradiometric assay (Immunotech, Marseille, France) for MONA LISA.
The HELENA Study. The recruitment and phenotyping of the adolescents in the HELENA cross-sectional study (www.helenastudy.com) were described in detail elsewhere. 34 Briefly, a total of 3865 adolescents (12-18 year old) were recruited between 2006 and 2007. Data were collected in a total of 10 centers in nine European countries. Subjects were randomly selected from schools by using a proportional cluster sampling method, and age was taken into account. One-third of the classes were randomly selected for blood collection (n ¼ 1155, the sample used in the statistical analyses). The protocol was approved by the appropriate investigational review board for each investigating center. Written informed consent was obtained from each adolescent and both of his or her parents or legal representatives. Participation in the study was voluntary.
At each center, trained researchers carried out comprehensive physical examinations, including weight, height, waist and hip circumferences and blood pressure measurements. The BMI was calculated as weight (kg) divided by height (m 2 ). Overweight was defined according to Cole et al. 35 who reported international cut off points for BMI by age and sex, corresponding to at least 25 kg m À 2 at the age of 18. Skin-fold thicknesses were measured at six sites (biceps, triceps, subscapular, suprailiac, thigh and calf) using a Holtain caliper (to the nearest 0.2 mm). 36 The reliability of skin-fold thickness measurements is known to be adequate for epidemiological surveys. 37 The overall score was calculated by summing the six skin-fold thicknesses. Mean skin-folds and circumferences were calculated from three consecutive measurements. Percentage of body fat was derived from the skin-fold measurements according to the equations published by Parizkova et al. 38 For bioelectrical impedance analysis measurements, a classical tetrapolar technique was used by means of BIA 101 AKERN SRL. Fat mass was then calculated using the software Bodygram V. 1.31 (Akern S.r.l. Bioresearch, Pontassieve, Italy) that uses the equations previously published by Sun et al.
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Venous blood samples were drawn after a 10-hour overnight fast. Blood samples were sent to a central laboratory (the Analytical Laboratory at the University of Bonn (IEL), Bonn, Germany). Serum triglycerides, high-density lipoprotein and low-density lipoprotein cholesterol and glucose levels were enzymatically assayed on the Dimension RxL clinical chemistry system (Dade Behring, Schwalbach, Germany). Blood for DNA extraction was collected in ethylene diamine tetra acetic acid K3 tubes, stored at the IEL and then sent to the Genomic Analysis Laboratory at the Institut Pasteur de Lille (Lille, France). DNA was extracted from white blood cells with the Puregene kit (QIAGEN, Courtaboeuf, France) and stored at À 20 1C.
Genotyping
The SNPs were genotyped using the Taqman technology in MONICA Lille or the Illumina technology in the MONA LISA Lille and HELENA samples. The mean genotyping success rate was 96.5%.
Reporter plasmids
The 2565-bp fragment corresponding to the intron 1 of the REV-ERBa gene in its two allelic forms (C and T) for rs2071427 was PCR amplified using the following primers: 5 0 -CCACCTCCATCTACGCCTTAT-3 0 (forward) and 5 0 -CTAGGGTGCCACTGTGCTCATC-3 0 (reverse). The resulting product was inserted into the pGL3-promoter luciferase reporter vector (Promega, Madison, WI, USA) to generate the pGL3 intron 1 REV-ERBa C::Luc and pGL3 intron 1 REV-ERBa T::Luc reporter plasmids. Insertion and sequence integrity was checked by direct sequencing.
Cell lines and transient transfections
The HepG2 (ATCC No. HB-8065, LGC Standards SARL, Molsheim, France) and HuH7 40 human hepatoma cell lines were cultured according to the manufacturer 0 s recommendations. Cells were grown at 60-70% confluence in 24-well plates and transfected with 250 ng of empty pGL3 promoter or of pGL3 intron 1 REV-ERBa C or pGL3 intron 1 REV-ERBa T::Luc reporter plasmids with FuGENE HD (Roche Applied Science, Meylan, France) (for HepG2) using a FuGENE:DNA ratio of 3:1 or with Lipofectamine 2000 (Invitrogen Life Technologies, St Aubin, France) (for HuH7) using a Lipofectamine:DNA ratio of 3:1 following the manufacturer 0 s instructions. Luciferase activities were measured 45 h after transfection using the Dual Luciferase Assay kit (Promega). The Firefly luciferase activity was normalized against the Renilla luciferase activity obtained by cotransfection of 15 ng of the pRL-CMV vector (Promega) for HepG2 or 1.5 ng of the pRL-TK vector (Promega) for HuH7.
Statistical analysis
Statistical analyses were performed with SAS 8.02 software (SAS Institute, Cary, NC, USA). Hardy-Weinberg equilibrium was tested using the w 2 test (1 degree of freedom). Intergroup comparisons of means were performed with a general linear model for all genetic models. The adjustment variables were age, gender, smoking habit, alcohol consumption and level of physical activity ( þ BMI for biochemical and clinical variables) in the MONICA and MONA LISA studies and were age, gender and center ( þ BMI for biochemical and clinical variables) in the HELENA study.
A Pearson w 2 test was used to compare genotype and allele distributions between groups. Multivariate logistic regression analyses were used to calculate the odds ratios for obesity or overweight, and were adjusted for age, gender, physical activity level, alcohol consumption and smoking status in both the MONICA and MONA LISA studies and for age, gender, center in the HELENA study.
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The pooled estimates were obtained with a fixed-effect meta-analysis using the metafor package in R 41 and were adjusted for age and gender. Haplotype frequencies were estimated using a stochastic version of the expectation-maximization algorithm, as implemented in Thesias software. 42 Table 1 and all respected the Hardy-Weinberg equilibrium (PX0.11).
RESULTS

SNPs in REV-
The associations between the five REV-ERBa SNPs and anthropometric (weight, waist and hip circumferences, BMI), biochemical (fasting plasma triglyceride, total cholesterol, high-density lipoprotein-cholesterol, low-density lipoprotein-cholesterol, glucose and insulin levels) and clinical (systolic and diastolic blood pressure) phenotypes were assessed in the MONICA Lille, MONA LISA Lille and HELENA samples. Only associations that were consistently significant at Po0.05 in the three independent samples were considered as relevant. Using this approach, we did not detect any association between rs883871, rs2102928, rs2269457 and rs2071570 and any variable (Supplementary Table 1 ). In contrast, we detected significant associations between rs2071427 and BMI in the MONICA Lille (P ¼ 0.02), MONA LISA Lille (P ¼ 0.02) and HELENA (P ¼ 0.03) studies (Table 2) . Indeed, in the MONICA Lille study, subjects with the TT genotype of rs2071427 had higher BMI ( þ 1.4 kg m À 2 ), compared with subjects bearing the C allele. In the MONA LISA Lille and HELENA studies, the minor T allele of rs2071427 was also associated with higher BMI ( þ 0.5 kg m À 2 in both studies). The T allele of rs2071427 was also associated with a higher percentage of body fat in the MONA LISA Lille and HELENA studies (P ¼ 0.05 and P ¼ 0.02, respectively). Moreover, in the HELENA study, all lower-body skin-fold thicknesses (suprailiac, thigh and calf skin-folds) were higher in T allele carriers than in CC adolescents ( Table 3 ). The fat-free mass was not altered.
As the genetic effect appeared to be sometimes dominant (in MONA LISA and HELENA), sometimes recessive (in MONICA), to improve statistical power, we pooled beta-coefficients (calculated under an additive model) from the three studies using a fixedeffect model. The T allele of the rs2071427 SNP was significantly associated with BMI (b ¼ 0.33±0.12 kg m À 2 , P ¼ 0.006) (Figure 1a ). There was no significant heterogeneity in the meta-analysis (P ¼ 0.39).
Haplotype analyses performed with the five SNPs did not add any further information (data not shown).
We then assessed the association between rs2071427 and the risk of developing obesity in the MONICA Lille (221 obese and 897 nonobese subjects) and MONA LISA Lille (346 obese and 1171 nonobese subjects) studies. In the HELENA study, We pooled odds ratios (calculated under an additive model) from the three studies using a fixed-effect model. The T allele of the rs2071427 SNP was significantly associated with a higher risk of overweight/obesity (OR ¼ 1.19 (1.04-1.34) , P ¼ 0.01) (Figure 1b) . There was no significant heterogeneity in the meta-analysis (P ¼ 0.13).
The rs2071427 SNP is located into intron 1 of REV-ERBa, a region known to contain numerous functional regulatory sites driving transcription of the mouse gene. 43 As this intronic sequence shows a high level of conservation between human and mouse (87% of the human intron 1 sequence is 71% identical to the mouse sequence), we hypothesized that this SNP may modulate REV-ERBa gene transcription. To test this hypothesis, we subcloned the intron 1 (2565 bp) encompassing the rs2071427 SNP into the pGL3-promoter luciferase reporter. The two alleles were obtained by site-directed mutagenesis. We next assessed in vitro, the potential influence of the SNP on REV-ERBa intron 1 activity in transient transfection assays using two different human hepatoma cell lines. Although the intron 1 stimulated the expression of the luciferase by more than twofold in HepG2 cells, no difference could be observed between the major C and minor T alleles ( Â 2.1-fold vs Â 2.5-fold, respectively) in these cells (Figure 2a) . In HuH7 cells, the REV-ERBa intron 1 exerted a repressive effect on luciferase activity indicating a different cellular context as compared with the HepG2 cells such as a different corepressor/coactivator balance but again, no difference could be observed between the C and T alleles ( Â 0.52-fold vs Â 0.49-fold, respectively) (Figure 2b ). These results indicate that although the REV-ERBa intron 1 has the potential to stimulate or repress transcription depending on the cellular context, the rs2071427 SNP does not seem to modulate its activity in human hepatocytederived cells cultured in vitro.
DISCUSSION
We report a significant and consistent association between the minor allele T allele of the REV-ERBa rs2071427 SNP and higher BMI in three population-based studies (mean allele effect ¼ þ 0.33 kg m À 2 ). Consequently, this allele was also associated with an average 19% higher risk of obesity or overweight. Interestingly, in adolescents, we could observe that this increase in BMI was in fact due to higher fat mass, especially in the lower part of the body, which may reflect higher subcutaneous adipose tissue. This study is the first to report an association between REV-ERBa SNPs and body fat mass. These results are supported by biological data that have linked REV-ERBa with adipogenesis. 24, 44 Fontaine et al. 11 have shown that REV-ERBa is an enhancer of adipogenesis, likely acting downstream PPARg. In fact, during adipocyte differentiation in 3T3-L1 cells, REV-ERBa mRNA levels decrease in the first 24 h and then increase. 45 In an opposite manner, REV-ERBa protein levels increase in the first 24 h and then decrease. The early increase in REV-ERBa protein is required for the mitotic events that are an obligatory step in adipocyte differentiation. 45 The identification of common genetic variants influencing BMI may lead to a better understanding of the biological basis of obesity. The meta-analysis of genome-wide association studies of BMI using data from 46 studies including up to 249, 796 REV-ERBa and fat mass in adult and young people L Goumidi et al individuals led to the identification of 32 loci. 46 The REV-ERBa locus was not one of these top hits. However, because of the very low statistical P-value threshold required in genome-wide association studies (Po5 Â 10
), nominal associations with REVERBa SNPs may have been unreported. Thus, a candidate gene approach, as in the present study, may help to detect associations between SNPs and metabolic disorders. Our findings, however, must be replicated in other population samples to confirm the link between REV-ERBa gene variability and BMI. To note, the association between rs2071427 and BMI was not altered after further adjustment for the FTO rs9939609 SNP (data available in the MONICA Lille and HELENA samples, data not shown).
The mouse ortholog of human REV-ERBa is expressed in multiple organs and tissues including the liver, adipose tissue, muscle, the hypothalamus and immune cells. Moreover, this gene which encodes a core circadian clock component, is expressed rhythmically with a very high amplitude and is also regulated by other signaling pathways such as the PPARa in liver and PPARg in adipose tissue. Consequently, the rs2071427 SNP is likely to interact with additional structural determinants in the REV-ERBa gene, in a tissue-specific manner or through complex interactions between several organs as well as in a time of day-dependent manner. To get more insights into the putative role of the intronic rs2071427 SNP in the regulation of REV-ERBa expression, we used a transient transfection approach in two human hepatoma cell lines as the liver is the prominent site of REV-ERBa expression. The lack of difference between the two alleles, irrespective of the cell context, may suggest that this SNP does not have a significant regulatory role in the liver. Ultimately, it might be possible that the rs2071427 SNP is not responsible for the observed associations and that it might be in linkage disequilibrium with (an)other functional SNP(s) that remain(s) to be determined.
Our study presents some strengths. One strength is that we covered the whole known genetic variability of the REV-ERBa gene by studying five TagSNPs. Rather than performing a potentially overconservative Bonferroni correction, we chose to reduce type-I errors by using three independent studies. Only significant associations in the three samples were considered. Moreover, we observed significant associations with BMI in both adults and adolescent population samples, thus preventing even more the risk of false-negative associations. Nevertheless, our data need to be replicated in other larger samples to be confirmed. We also tried to assess the in vitro functional impact of the rs2071427 SNP in two cell line types but this SNP did not seem to have a significant regulatory role in the liver at least in cell culture systems.
In conclusion, our study showed that the REV-ERBa rs2071427 polymorphism modulates body fat mass in both adult and young people. Figure 1 . Meta-analysis of the effect of the REV-ERBa rs2071427 SNP on body mass index (BMI) (a) and overweight/obesity risk (b) in the three studies. Per-allele effect was estimated for BMI (a) or for the risk of overweight/obesity (b) in the pooled MONICA Lille, MONA LISA Lille and HELENA studies using a fixed-effect model. Odds ratios (ORs) and P values were adjusted for age and gender. 
